S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
NASDAQ:EXEL

Exelixis Stock Forecast, Price & News

$22.33
+1.02 (+4.79 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.08
Now: $22.33
$22.35
50-Day Range
$21.31
MA: $22.46
$23.81
52-Week Range
$13.67
Now: $22.33
$27.80
Volume2.01 million shs
Average Volume2.42 million shs
Market Capitalization$6.97 billion
P/E Ratio46.52
Dividend YieldN/A
Beta1.21
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.
Exelixis logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000
Employees773
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$967.78 million
Cash Flow$0.99 per share
Book Value$5.55 per share

Profitability

Net Income$321.01 million

Miscellaneous

Market Cap$6.97 billion
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.90 out of 5 stars

Medical Sector

106th out of 1,969 stocks

Commercial Physical Research Industry

3rd out of 42 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
$22.33
+1.02 (+4.79 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Exelixis (NASDAQ:EXEL) Frequently Asked Questions

Is Exelixis a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Exelixis stock.
View analyst ratings for Exelixis
or view top-rated stocks.

What stocks does MarketBeat like better than Exelixis?

Wall Street analysts have given Exelixis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Exelixis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Exelixis' next earnings date?

Exelixis is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Exelixis
.

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) released its quarterly earnings data on Tuesday, February, 9th. The biotechnology company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.05 by $0.04. The biotechnology company earned $270.10 million during the quarter, compared to the consensus estimate of $261.44 million. Exelixis had a net margin of 15.88% and a trailing twelve-month return on equity of 8.55%. The business's quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.26 earnings per share.
View Exelixis' earnings history
.

How has Exelixis' stock price been impacted by COVID-19 (Coronavirus)?

Exelixis' stock was trading at $17.32 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, EXEL shares have increased by 28.9% and is now trading at $22.33.
View which stocks have been most impacted by COVID-19
.

What guidance has Exelixis issued on next quarter's earnings?

Exelixis issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.15-1.25 billion, compared to the consensus revenue estimate of $1.2 billion.

What price target have analysts set for EXEL?

9 equities research analysts have issued 1-year price targets for Exelixis' shares. Their forecasts range from $27.00 to $40.00. On average, they anticipate Exelixis' share price to reach $32.11 in the next year. This suggests a possible upside of 43.8% from the stock's current price.
View analysts' price targets for Exelixis
or view top-rated stocks among Wall Street analysts.

Who are Exelixis' key executives?

Exelixis' management team includes the following people:
  • Dr. Stelios Papadopoulos Ph.D., Co-Founder & Independent Chairman (Age 73, Pay $98k)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 60, Pay $2.13M)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 53, Pay $942.26k)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 60, Pay $784.71k)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 52, Pay $838.67k)
  • Dr. Gisela M. Schwab, Pres of Product Devel. & Medical Affairs and Chief Medical Officer (Age 64, Pay $1.13M)
  • Dr. Dana T. Aftab, Exec. VP of Bus. Operations
  • Ms. Susan T. Hubbard, Exec. VP of Public Affairs & Investor Relations
  • Mr. Jonathan Berndt, VP of Sales
  • Mr. Gregg Bernier, VP of Marketing

What is Michael M. Morrissey's approval rating as Exelixis' CEO?

32 employees have rated Exelixis CEO Michael M. Morrissey on Glassdoor.com. Michael M. Morrissey has an approval rating of 79% among Exelixis' employees.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Alibaba Group (BABA), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Vertex Pharmaceuticals (VRTX) and AbbVie (ABBV).

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

Who are Exelixis' major shareholders?

Exelixis' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (10.12%), Renaissance Technologies LLC (6.99%), Price T Rowe Associates Inc. MD (5.67%), Meditor Group Ltd (4.06%), JPMorgan Chase & Co. (3.74%) and First Trust Advisors LP (1.08%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi.
View institutional ownership trends for Exelixis
.

Which major investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Renaissance Technologies LLC, Blair William & Co. IL, First Trust Advisors LP, Chicago Capital LLC, Lord Abbett & CO. LLC, Meditor Group Ltd, and Burney Co.. Company insiders that have sold Exelixis company stock in the last year include Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, Gisela Schwab, Jack L Wyszomierski, Jeffrey Hessekiel, Lance Willsey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos, and Vincent T Marchesi.
View insider buying and selling activity for Exelixis
or view top insider-selling stocks.

Which major investors are buying Exelixis stock?

EXEL stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Norges Bank, Assenagon Asset Management S.A., JPMorgan Chase & Co., Candriam Luxembourg S.C.A., BlackRock Inc., Scout Investments Inc., and FIL Ltd.
View insider buying and selling activity for Exelixis
or or view top insider-buying stocks.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $22.33.

How much money does Exelixis make?

Exelixis has a market capitalization of $6.97 billion and generates $967.78 million in revenue each year. The biotechnology company earns $321.01 million in net income (profit) each year or $1.02 on an earnings per share basis.

How many employees does Exelixis have?

Exelixis employs 773 workers across the globe.

What is Exelixis' official website?

The official website for Exelixis is www.exelixis.com.

Where are Exelixis' headquarters?

Exelixis is headquartered at 1851 Harbor Bay Parkway, Alameda CA, 94502.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.